Randomized clinical trial of postoperative fondaparinux versus perioperative dalteparin for prevention of venous thromboembolism in high-risk abdominal surgery
Why the study?
Does postoperative fondaparinux prevent venous thromboembolism compared to perioperative dalteparin in patients undergoing major abdominal surgery?
Population
Patients scheduled for major abdominal surgery under general anaesthesia
Comparison
Fondaparinux 2.5 mg once-daily subcutaneous… vs Dalteparin 5000 units once-daily subcutaneous…
Design
RCT, randomized, double-blind double-dummy
Follow-up
up until day 10
Authors
Discussion
Loading...
Member takes
Implication
Postoperative fondaparinux offers a viable VTE prophylaxis option after major abdominal surgery; confirms non-inferiority to perioperative dalteparin in this RCT.
Structured PICO
Does postoperative fondaparinux prevent venous thromboembolism compared to perioperative dalteparin in patients undergoing major abdominal surgery?
P
Population
Patients scheduled for major abdominal surgery under general anaesthesia
I
Intervention
Fondaparinux 2.5 mg once-daily subcutaneous injections for 5-9 days, started 6 h after surgery
C
Comparator
Dalteparin 5000 units once-daily subcutaneous injections for 5-9 days (first two doses 2500 units each, given 2 h before surgery and 12 h after preoperative administration)
O
Outcome
Composite of deep vein thrombosis detected by bilateral venography and symptomatic, confirmed deep vein thrombosis or pulmonary embolism up until day 10composite
Postoperative fondaparinux is non-inferior to perioperative dalteparin for the prevention of venous thromboembolism in patients undergoing high-risk abdominal surgery.
Cite This Study
Agnelli et al. (2005) studied this question.